Aurobindo Pharma to acquire commercial operations and three units of Sandoz in US for $900 mn

Aurobindo Pharma

Hyderabad: The wholly owned subsidiary of Hyderabad-based Aurobindo Pharma, Aurobindo Pharma USA Inc, has entered into an agreement to acquire commercial operations and three manufacturing facilities in the US from Sandoz Inc, USA, a division of Novartis, for $900 million.

The acquisition will include dermatology and oral solids business from Sandoz.

The all-cash deal is expected to give Aurobindo access to 300 products and net sales of over $900 million within the first year of the acquisition, Aurobindo informed the BSE in a filing.